4T1

Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice

Retrieved on: 
Tuesday, October 17, 2023
Immunosuppression, Survival, Div, Stanford University School of Medicine, MD, Manuscript, PD-L1, Surgical oncology, UNO, 4T1, Administration, Immunotherapy, Associate, Science, PD-1, Pharmaceutical industry, Vaccine, M1, Surgery, Cell

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced today the publication of pre-clinical data demonstrating that its proprietary technology reduces immunosuppression and creates a favorable microenvironment that can contribute to immune potentiation.

Key Points: 
  • The data were published in an article entitled, “Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice,” in the peer-reviewed journal Cells.
  • The article is available on the Cells website.
  • “The combination of UNO and anti-mPD-1 resulted in a potent, synergistic immune response,” stated Dr. Hila Confino, Head of In Vivo Studies.
  • “I am excited for the presentation of our initial clinical data at SITC.”

Onchilles Pharma Presents at AACR 2023 New Preclinical Data on N17350, a First-in-Class Immuno-Oncology Drug Candidate with Broad, Potent, and Direct Tumor Killing Activity

Retrieved on: 
Wednesday, April 19, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Pharma, AACR, Therapy, Neutrophil, Survival, Cancer, American Association for Cancer Research, Toxicity, Patient, Data, Immune system, 4T1, Pharmaceutical industry, Vaccine

The data demonstrate N17350, as a monotherapy or in combination with checkpoint inhibitors, abrogates tumor growth, induces a robust immune signature with the potential to establish durable remission, and demonstrates no acquired resistance.

Key Points: 
  • The data demonstrate N17350, as a monotherapy or in combination with checkpoint inhibitors, abrogates tumor growth, induces a robust immune signature with the potential to establish durable remission, and demonstrates no acquired resistance.
  • These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place in Orlando.
  • “We have generated a substantial amount of preclinical data demonstrating N17350 is unlike any other immuno-oncology therapeutic approach,” said Court R. Turner J.D., Co-Founder & Executive Chair of Onchilles Pharma.
  • “These data compel us to move N17350 into the clinic to help patients with limited treatment options.”

Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
CPI, IND, Natural killer T cell, Nature, Doctor of Philosophy, Syngenic, U.S. Securities and Exchange Commission, Tumor microenvironment, Annual general meeting, Immunotherapy, 4T1, Private Securities Litigation Reform Act, TGF, Society for Immunotherapy of Cancer, COVID-19, Securities Act of 1933, NASDAQ, Securities Exchange Act of 1934, SITC, COVID-19 CPI, Company, Cancer, Neoplasm, Program, Immune system, Growth, Security (finance), Animal, Industry, Society, Phenotype, Pharmaceutical industry, Medical imaging, Poster, Corbus, Facebook

NORWOOD, Mass., Nov. 10, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology company, is presenting new preclinical data for CRB-601 today in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston.

Key Points: 
  • NORWOOD, Mass., Nov. 10, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology company, is presenting new preclinical data for CRB-601 today in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston.
  • The latest preclinical data demonstrate significant tumor growth inhibition by CRB-601 as a single agent and in combination with anti-PD-1 treatment in the syngeneic murine tumor models MC38 and EMT6.
  • CRB-601 is the only anti-v8 targeting agent known to demonstrate such an effect in these models to date.
  • The anti-tumor effects in the immune excluded EMT6 model correlated with changes in the immune cell populations in the tumor microenvironment.

DGAP-News: DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

Retrieved on: 
Wednesday, September 29, 2021
Biotechnology, Infection, Therapy, Mouse, Cell death, Animal, 4T1, Vaccine, GLP, News, FDA, CSE, Cancer, Engineering, Catastrophic illness, DGAP, PDX, Marketing, CEO, Death, COVID, Company, Antibody, Control, DC, HPV, Technology, ADC, Research, Cell, Forward-looking statement, Breast cancer, Industry, Protein, Security (finance), Pharmaceutical industry

"We are actively pursuing our AccuTOX program to initiate a Phase I trial against breast cancer in Q1-Q2 of 2022" said Sebastien Plouffe, CEO of Defence Therapeutics.

Key Points: 
  • "We are actively pursuing our AccuTOX program to initiate a Phase I trial against breast cancer in Q1-Q2 of 2022" said Sebastien Plouffe, CEO of Defence Therapeutics.
  • "We will re-enforce our data by showing how potent is AccuTOX-001 at killing of breast cancer in various animal models including the use of patient-derived xenografts (PDX).
  • Once completed, this data along with the GLP study scheduled in Q4 of 2021 will be compiled and presented to the FDA to have clearance for a Phase I trial against breast cancer.
  • Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform.

Therapeutic Solutions International Reports Successful Treatment of Breast Cancer using StemVacs™ Cellular Immunotherapy

Retrieved on: 
Tuesday, January 19, 2021
Branches of biology, Clinical medicine, Medicine, 4T1, Immunotherapy, Natural killer cell, Breast cancer

OCEANSIDE, Calif., Jan. 19, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported positive animal data in the 4T1 breast cancer model using its clinically tested StemVacs cellular immunotherapy.

Key Points: 
  • OCEANSIDE, Calif., Jan. 19, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported positive animal data in the 4T1 breast cancer model using its clinically tested StemVacs cellular immunotherapy.
  • In a series of experiments, it was demonstrated that StemVacs administration resulted in a) regression of established breast cancer in mice; b) that regression was dependent on natural killer cells, and c) that immunity to breast cancer could be transferred by CD4 T cells to nave mice.
  • "Therapeutic Solutions International is a 'science-driven' organization," said Timothy Dixon, President and CEO.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

HER2-Negative Breast Cancer Market Outlook to 2028: 9 New Entrants Forecast to Launch in 8 Major Markets

Retrieved on: 
Thursday, November 19, 2020
Clinical medicine, Tyrosine kinase receptors, Cancer, Health, HER2/neu, Triple-negative breast cancer, Breast cancer, Epidermal growth factor receptor, Breast cancer classification, 4T1

Human epidermal growth factor receptor type 2 (HER2)-negative breast cancer is one of the most common cancer in the world and the most common cancer in women worldwide.

Key Points: 
  • Human epidermal growth factor receptor type 2 (HER2)-negative breast cancer is one of the most common cancer in the world and the most common cancer in women worldwide.
  • HER2-negative breast cancer can generally be subdivided into two major groups: HER2-, estrogen receptor (ER)+ and/or progesterone receptor (PR)+ and HER2-, ER-, and PR- (triple-negative breast cancer, or TNBC).
  • Topline HER2-negative breast cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Analysis of the current and future market competition in the global HER2-negative breast cancer therapeutics market.

Therapeutic Solutions International Reports Augmentation of Immunotherapy Efficacy in Breast Cancer Model Utilizing Patented NanoStilbene™ Nutraceutical Product

Retrieved on: 
Tuesday, November 10, 2020
Clinical medicine, Medicine, 4T1, Cancer immunotherapy, Ipilimumab, Immunotherapy, Medical specialties

OCEANSIDE, Calif., Nov. 10, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today novel data supporting utilization of the Company's NanoStilbene product for enhancement of cancer immunotherapy clinical trials.

Key Points: 
  • OCEANSIDE, Calif., Nov. 10, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today novel data supporting utilization of the Company's NanoStilbene product for enhancement of cancer immunotherapy clinical trials.
  • In the experiments disclosed today, Company collaborators injected mice with a type of breast cancer termed 4T1.
  • The combination of NanoStilbene with Yervoy leads to not only inhibition of tumor growth, but actual regression.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR Conference on Tumor Immunology and Immunotherapy

Retrieved on: 
Monday, October 19, 2020
Oncology, Cancer, Medical specialties, Clinical medicine, 4T1, Cancer immunology, Metástasis, Colorectal cancer

These data were included in a presentation by Hila Confino, PhD of Beyond Air, at the AACR Conference on Tumor Immunology and Immunotherapy, which is being held from October 19th to 20th.

Key Points: 
  • These data were included in a presentation by Hila Confino, PhD of Beyond Air, at the AACR Conference on Tumor Immunology and Immunotherapy, which is being held from October 19th to 20th.
  • In the studies, colon and breast tumor-bearing mice (CT26 and 4T1 models, respectively) received a single treatment with high concentration gNO intratumorally.
  • Up to 21 days after gNO administration to the primary tumor, all mice were inoculated with a challenge tumor and growth of that tumor was tracked.
  • Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths.

Therapeutic Solutions International Reports QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer

Retrieved on: 
Thursday, June 11, 2020
Medical specialties, Medicine, 4T1, Metástasis, Cancer, Health, Tumor microenvironment

OCEANSIDE, California, June 11, 2020 /PRNewswire/ --Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today novel data suggesting that QuadraMune administration reduces the number and activity of immune inhibitory cells termed "myeloid suppressor cells."

Key Points: 
  • OCEANSIDE, California, June 11, 2020 /PRNewswire/ --Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today novel data suggesting that QuadraMune administration reduces the number and activity of immune inhibitory cells termed "myeloid suppressor cells."
  • In a series of animal studies using the triple-negative breast cancer 4T1 mouse model, the Company showed that administration of QuadraMune reduced lung metastasis on its own and increased efficacy of a "cancer vaccine".
  • "In the current patent, we cover the use of QuadraMune to reduce these immune inhibitory cells, called Myeloid Suppressor cells, which act as cancer's shield against the immune response."
  • "Myeloid Suppressor Cells, originally described by Dr. Sharwan Singhal as "Natural Suppressor" cells, have been shown to correlate with faster cancer death and treatment unresponsiveness," said Timothy Dixon, President, and CEO of the Company.

OB-002 Significantly Reduces Bone Metastasis in a Murine Model of Breast Cancer

Retrieved on: 
Thursday, October 31, 2019
RTT, Breast cancer, Health, Metastatic breast cancer, 4T1, Medicine, Bone metastasis, Metástasis, Cancer, Mouse models of breast cancer metastasis

OTTAWA, Ontario, Oct. 31, 2019 /PRNewswire/ -- Orion Biotechnology Canada, Ltd.today announced that OB-002 was able to significantly reduce bone metastasis in a murine model of breast cancer.

Key Points: 
  • OTTAWA, Ontario, Oct. 31, 2019 /PRNewswire/ -- Orion Biotechnology Canada, Ltd.today announced that OB-002 was able to significantly reduce bone metastasis in a murine model of breast cancer.
  • The 4T1 breast cancer cells were transfected with firefly luciferase that allowed bioluminescent quantification of metastatic disease.
  • "Unfortunately, bone is the most common site of metastatic breast cancer (Ording AGet al., Clin Exp Metastasis 2017) and approximately 70% of women dying from breast cancer have bone metastases (Awolaran Oet al., Breast 2016).
  • Bone metastasis is a frequent and debilitating complication of breast cancer and so these preliminary preclinical data are very encouraging."